“OXXEL (Oxaliplatin plus Xeloda) versus OXAFAFU (Oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis”

Research output: Contribution to conferenceOther

Original languageUndefined/Unknown
Pagesxi47-xi47
Publication statusPublished - 2006

Cite this